Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL
Anna Vardi(G. Papanikolaou General Hospital), Paolo Ghia(Vita-Salute San Raffaele University), Antonis Dagklis(Vita-Salute San Raffaele University), Sallie D. Allgood(Duke Medical Center), Júlia Almeida(Universidad de Salamanca), Lydia Scarfò(IRCCS Ospedale San Raffaele), Tait D. Shanafelt(Mayo Clinic), Silvio Veronese(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Darren Newton(University of Leeds), Marco Montillo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Κώστας Σταματόπουλος(Centre for Research and Technology Hellas), Mark C. Lanasa(Duke Medical Center), Arancha Rodríguez‐Caballero(Universidad de Salamanca), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Alberto Órfão(Universidad de Salamanca), Ester Orlandi(University of Pavia), Andy C. Rawstron(University of Leeds), Diane F. Jelinek(Mayo Clinic in Arizona), Fiona Bennett(Leeds Teaching Hospitals NHS Trust)
Cited by 93
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Executive Leadership and Physician Well-being
|Mayo Clinic Proceedings|2016|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k